1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says
Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the...To view the full article, register now.
Already a subscriber? Click here to view full article